Because of the risks associated with G6PD deficiency and primaquine use, the malaria treatment guidelines of the World Health Organization (WHO) recommend that “the G6PD status of patients should be used to guide administration of primaquine” [11]. This evidence concerns the gene G6PD and malaria.